Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of CPL207280 (GPR40 agonist) in type 2 diabetes mellitus
2021-002947-32Phase 2Completed
- Sponsor
- Celon Pharma S.A.
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing CPL207280-51 arm with Placebo arm (2 arms). Primary endpoint: Primary: Change in plasma glucose AUC0–3h during OGTT from Day -1 to Day 14. Started Jul 2021; status: completed.
02
Drugs
CPL207280
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2021-002947-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002947-32.